European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy

On 21 November 2016, the European Commission issued a marketing authorisation valid throughout the European Union for ixazomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Ixazomib was evalu...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:ESMO Open
Asıl Yazarlar: Tzogani, Kyriaki, Florez, Beatriz, Markey, Greg, Caleno, Mariapaola, Olimpieri, Odoardo Maria, Melchiorri, Daniela, Hovgaard, Doris Johanna, Sarac, Sinan Bardakci, Penttilä, Karri, Lapveteläinen, Tuomo, Salmonson, Tomas, Bergh, Jonas, Gisselbrecht, Christian, Pignatti, Francesco
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2019
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6735670/
https://ncbi.nlm.nih.gov/pubmed/31555488
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000570
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller